Work

Supplementary Figure S3 from A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Sensitivity of CD74-ROS1D2033N to a spectrum of ROS1 kinase inhibitors. Cell growth and viability of Ba/F3 cells expressing native CD74-ROS1 or CD74-ROS1D2033N after 72 h exposure to (A) foretinib, (B) PF-06463922, (C) ceritinib, and (D) brigatinib. Results are shown as mean viability normalized to vehicle-treated control {plus minus} SEM (n = 3 to 6). (E) Table listing inhibitor IC50 (nM) for native versus ROS1D2033N mutant. (F) Graph depicts fold increase in IC50 (nM) for Ba/F3 cells expressing CD74-ROS1D2033N compared to native CD74-ROS1.

DOI: 10.1158/1078-0432.22458380.v1

Authors: Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, Monika A. Davare

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361917535

Cites:

Cited by:

Related to: 10